343 related articles for article (PubMed ID: 31370980)
1. A comparison of adherence, outcomes, and costs among opioid use disorder Medicaid patients treated with buprenorphine and methadone: A view from the payer perspective.
Kinsky S; Houck PR; Mayes K; Loveland D; Daley D; Schuster JM
J Subst Abuse Treat; 2019 Sep; 104():15-21. PubMed ID: 31370980
[TBL] [Abstract][Full Text] [Related]
2. Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History.
Clark RE; Baxter JD; Aweh G; O'Connell E; Fisher WH; Barton BA
J Subst Abuse Treat; 2015 Oct; 57():75-80. PubMed ID: 25997674
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Treatments for Opioid Use Disorder.
Fairley M; Humphreys K; Joyce VR; Bounthavong M; Trafton J; Combs A; Oliva EM; Goldhaber-Fiebert JD; Asch SM; Brandeau ML; Owens DK
JAMA Psychiatry; 2021 Jul; 78(7):767-777. PubMed ID: 33787832
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation: a comparison of methadone versus buprenorphine for opiate substitution treatment.
Maas J; Barton G; Maskrey V; Pinto H; Holland R
Drug Alcohol Depend; 2013 Dec; 133(2):494-501. PubMed ID: 23962419
[TBL] [Abstract][Full Text] [Related]
5. Opioid use disorder in Germany: healthcare costs of patients in opioid maintenance treatment.
Reimer J; Vogelmann T; Trümper D; Scherbaum N
Subst Abuse Treat Prev Policy; 2019 Dec; 14(1):57. PubMed ID: 31842942
[TBL] [Abstract][Full Text] [Related]
6. Age related medication for addiction treatment (MAT) use for opioid use disorder among Medicaid-insured patients in New York.
Neighbors CJ; Choi S; Healy S; Yerneni R; Sun T; Shapoval L
Subst Abuse Treat Prev Policy; 2019 Jun; 14(1):28. PubMed ID: 31238952
[TBL] [Abstract][Full Text] [Related]
7. Healthcare utilization and costs associated with treatment for opioid dependence.
Shah A; Duncan M; Atreja N; Tai KS; Gore M
J Med Econ; 2018 Apr; 21(4):406-415. PubMed ID: 29320915
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
Wakeman SE; Larochelle MR; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM
JAMA Netw Open; 2020 Feb; 3(2):e1920622. PubMed ID: 32022884
[TBL] [Abstract][Full Text] [Related]
9. Management of opioid-dependent patients: comparison of the cost associated with use of buprenorphine/naloxone or methadone, and their interactions with concomitant treatments for infectious or psychiatric comorbidities.
Roncero C; Domínguez-Hernández R; Díaz T; Fernández JM; Forcada R; Martínez JM; Seijo P; Terán A; Oyagüez I
Adicciones; 2015 Sep; 27(3):179-89. PubMed ID: 26437312
[TBL] [Abstract][Full Text] [Related]
10. Responses among substance abuse treatment providers to the opioid epidemic in the USA: Variations in buprenorphine and methadone treatment by geography, operational, and payment characteristics, 2007-16.
Yang JC; Roman-Urrestarazu A; Brayne C
PLoS One; 2020; 15(3):e0229787. PubMed ID: 32126120
[TBL] [Abstract][Full Text] [Related]
11. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
[TBL] [Abstract][Full Text] [Related]
12. Receipt of Timely Addiction Treatment and Association of Early Medication Treatment With Retention in Care Among Youths With Opioid Use Disorder.
Hadland SE; Bagley SM; Rodean J; Silverstein M; Levy S; Larochelle MR; Samet JH; Zima BT
JAMA Pediatr; 2018 Nov; 172(11):1029-1037. PubMed ID: 30208470
[TBL] [Abstract][Full Text] [Related]
13. A comparison of buprenorphine and psychosocial treatment outcomes in psychosocial and medical settings.
Presnall NJ; Wolf DAPS; Brown DS; Beeler-Stinn S; Grucza RA
J Subst Abuse Treat; 2019 Sep; 104():135-143. PubMed ID: 31370977
[TBL] [Abstract][Full Text] [Related]
14. Predictors of Medication Utilization for Opioid Use Disorder Among Medicaid-Insured HIV Patients in New York.
Choi S; Yerneni R; Healy S; Goyal M; Neighbors CJ
Am J Addict; 2020 Mar; 29(2):151-154. PubMed ID: 31951083
[TBL] [Abstract][Full Text] [Related]
15. Slow release oral morphine versus methadone for opioid use disorder in the fentanyl era (pRESTO): Protocol for a non-inferiority randomized clinical trial.
Socias ME; Wood E; Dong H; Brar R; Bach P; Murphy SM; Fairbairn N
Contemp Clin Trials; 2020 Apr; 91():105993. PubMed ID: 32194251
[TBL] [Abstract][Full Text] [Related]
16. Opioid use disorder during pregnancy in Tennessee: expediency vs. science.
Martin PR; Finlayson AJ
Am J Drug Alcohol Abuse; 2015; 41(5):367-70. PubMed ID: 26186388
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of full and partial opioid agonists for opioid use disorder in outpatient settings: United States healthcare sector perspective.
Choi SA; Yan CH; Gastala NM; Touchette DR; Stranges PM
J Subst Use Addict Treat; 2024 May; 160():209237. PubMed ID: 38061629
[TBL] [Abstract][Full Text] [Related]
18. Buprenorphine for opiate addiction: potential economic impact.
Rosenheck R; Kosten T
Drug Alcohol Depend; 2001 Aug; 63(3):253-62. PubMed ID: 11418229
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and Receipt of Medication Treatment Among Young Adults Who Experience a Nonfatal Opioid-Related Overdose.
Bagley SM; Larochelle MR; Xuan Z; Wang N; Patel A; Bernson D; Silverstein M; Hadland SE; Land T; Samet JH; Walley AY
Ann Emerg Med; 2020 Jan; 75(1):29-38. PubMed ID: 31591014
[TBL] [Abstract][Full Text] [Related]
20. A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees.
Stein BD; Dick AW; Sorbero M; Gordon AJ; Burns RM; Leslie DL; Pacula RL
Subst Abus; 2018; 39(4):419-425. PubMed ID: 29932847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]